22540-50-7

Usage

Uses

6-Oxopiperidine-3-carboxylic Acid can be used to treat progranulin associated disorders.

Upstream product

• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 
• 1356405-59-8 1-(2,4-dimethoxybenzyl)-6-oxopiperidine-3-carboxylic acid 
• 1356405-58-7 1-(2,4-dimethoxybenzyl)-6-oxopiperidine-3-carboxylic acid methyl ester 
• 5621-44-3 dimethyl 2-methylenepentanedioate 
• 71381-75-4 N-(tert-butyloxycarbonyl)nipecotic acid 

Downstream Products

• 1372144-04-1 C₃₀H₄₉N₅O₃ 
• 1426402-70-1 6-oxopiperidine-3-carboxylic acid [1-phenyl-5-(3-propylphenyl)-1H-pyrazol-3-yl]amide 
• 146059-77-0 5-(hydroxymethyl)piperidin-2-one 
• 1412451-01-4 C₂₃H₂₇N₃O₂S 
• 1412451-02-5 C₂₃H₂₇N₃O₂S 
• 1359857-98-9 C₂₁H₂₃N₃O₃S 
• 1142004-83-8 (rac)-N-(6-(2-methoxyphenyl)pyrimidin-4-yl)-6-oxopiperidine-3-carboxamide 
• 146059-76-9 ethyl 6-oxopiperidine-3-carboxylate 

Relevant academic research and scientific papers

PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention provides a pyrazole compound of the following general Formula [1b] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use wherein each symbol is the same as defined in the description

NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS

Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.

2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids

4-Deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acid derivatives are provided as agents useful for treatment susceptible neoplasms in mammals. Pharmaceutical formulations and intermediates are also provided.